Rapamycin and Retatrutide Interaction: Monitor | Peptide Database

Join others researching VIP — share findings, ask questions, and learn from real experiences Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions. VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.

Meldonium is increasingly used in the performance enhancement community as an adjunctive agent to protect the heart during anabolic steroid cycles. Supraphysiological androgen use is associated with left ventricular hypertrophy, impaired diastolic function, reduced ejection fraction, and accelerated atherosclerosis. Meldonium's ability to optimize cardiac energy metabolism and reduce toxic lipid intermediates may mitigate some of these effects, though direct clinical evidence in this specific context is limited to anecdotal and observational data. By shifting fuel utilization from fatty acids toward glucose, meldonium may improve aerobic efficiency under submaximal exercise conditions. Athletes in Eastern European countries have used meldonium for decades to support training capacity and recovery. The metabolic shift may spare glycogen during prolonged activity and reduce post-exercise oxidative stress. This use drove WADA's decision to ban the substance. In Baltic states and Russia, meldonium is an approved prescription drug for the treatment of stable angina pectoris and chronic ischemic heart disease. Clinical trials conducted primarily in Latvia and Russia have demonstrated reductions in angina frequency, improved exercise tolerance on treadmill testing, and reduced nitroglycerin consumption when meldonium is added to standard antianginal therapy. Meldonium has been investigated as an adjunctive therapy in chronic heart failure, where impaired cardiac energy metabolism contributes to disease progression. Small trials have reported improvements in exercise capacity and quality-of-life scores when meldonium was added to standard heart failure regimens. Larger-scale, Western-standard randomized controlled trials are lacking. The drug is prescribed in some Eastern European countries for acute and chronic cerebrovascular insufficiency. Its vasodilatory effects via nitric oxide stimulation and metabolic optimization may offer neuroprotective benefits during ischemic events. Evidence is primarily from non-Western clinical trials.